WHO ICTRP trial
Phase Ib/II Study of the Combination of Tucidinostat and Rituximab in Patients…
JPRN-jRCT2041210129 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCT2041210129 |
|---|---|
| Public title | Phase Ib/II Study of the Combination of Tucidinostat and Rituximab in Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma |
| Scientific title | Phase Ib/II Study of the Combination of Tucidinostat and Rituximab in Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma - ME2205-1 |
| Primary sponsor | Hatake Kiyohiko |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 1-2 |
| Conditions | B-cell Non-Hodgkin's Lymphoma |
| Interventions | Patients will receive tucidinostat at 40 mg QD twice weekly with a 3 to 4 day interval between doses and rituximab at 375 mg/m^2 on Day 1 of each Cycle in 21 day treatment cycles |
| Registration date | Jan 19, 2022 |
| Target size | 71 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: